PMID- 38454397
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240311
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Mar 7
TI  - A network meta-analysis evaluating the efficacy and safety of adjuvant therapy 
      after nephrectomy in renal cell carcinoma.
PG  - 55
LID - 10.1186/s12894-024-01441-8 [doi]
LID - 55
AB  - BACKGROUND: In the past few years, there has been a continuous rise in the 
      occurrence of renal cell carcinoma (RCC), with RCC recurrence becoming the 
      primary factor behind fatalities. Despite numerous clinical trials, the impact of 
      different medications on the long-term survival of patients with RCC after 
      surgery remains uncertain. This network meta-analysis aimed to evaluate the 
      impact of various medications on the survival and safety of drugs in individuals 
      with RCC following nephrectomy. METHODS: We conducted a thorough search in 
      various databases, including CNKI, WAN FANG DATA, VIP, Web of Science, Cochrane 
      Library (CENTRAL), PubMed, Scopus, and Embase, for articles published prior to 
      June 2, 2023. This meta-analysis incorporated randomized controlled trials 
      (RCTs). RESULTS: The analysis included 17 studies with 14,298 participants. The 
      findings from the disease-free survival (DFS) analysis indicated that 
      pembrolizumab demonstrated efficacy in enhancing DFS among patients with RCC 
      following nephrectomy when compared to the placebo group (HR = 0.83, 95%CI 0.70 
      to 0.99). None of the drugs included in the study significantly improved overall 
      survival (OS) and recurrence-free survival (RFS) after nephrectomy. For adverse 
      events (AEs), sorafenib, pazopanib, sunitinib, and nivolumab plus ipilimumab 
      interventions showed a higher incidence of adverse events compared with placebo. 
      CONCLUSION: The network meta-analysis yielded strong evidence indicating that 
      pembrolizumab could potentially enhance DFS in patients with RCC following 
      nephrectomy, surpassing the effectiveness of a placebo.
CI  - (c) 2024. The Author(s).
FAU - Guo, Lingyu
AU  - Guo L
AD  - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, 157 West Fifth Road, Xi'an, 710000, China.
FAU - An, Tian
AU  - An T
AD  - Department of Dermatology and Plastic Surgery, The Second Affiliated Hospital of 
      Shaanxi University of Traditional Chinese Medicine, Xianyang, China.
FAU - Huang, Zhixin
AU  - Huang Z
AD  - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, 157 West Fifth Road, Xi'an, 710000, China.
FAU - Chong, Tie
AU  - Chong T
AD  - Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, 157 West Fifth Road, Xi'an, 710000, China. chongtie@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20240307
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/drug therapy/surgery/pathology
MH  - *Kidney Neoplasms/drug therapy/surgery/pathology
MH  - Network Meta-Analysis
MH  - Chemotherapy, Adjuvant
MH  - Neoplasm Recurrence, Local/surgery
MH  - Nephrectomy
PMC - PMC10921661
OTO - NOTNLM
OT  - Adjuvant therapy
OT  - Efficacy
OT  - Network meta-analysis
OT  - Renal cell carcinoma
COIS- The authors declare no competing interests.
EDAT- 2024/03/08 06:43
MHDA- 2024/03/11 06:42
PMCR- 2024/03/07
CRDT- 2024/03/08 00:36
PHST- 2023/12/06 00:00 [received]
PHST- 2024/02/28 00:00 [accepted]
PHST- 2024/03/11 06:42 [medline]
PHST- 2024/03/08 06:43 [pubmed]
PHST- 2024/03/08 00:36 [entrez]
PHST- 2024/03/07 00:00 [pmc-release]
AID - 10.1186/s12894-024-01441-8 [pii]
AID - 1441 [pii]
AID - 10.1186/s12894-024-01441-8 [doi]
PST - epublish
SO  - BMC Urol. 2024 Mar 7;24(1):55. doi: 10.1186/s12894-024-01441-8.